Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease

Published:2007-06-01 Issue:2 Volume:1 Page:287-294
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hep Intl

Author:

Ichikawa Tatsuki,Nakao Kazuhiko,Hamasaki Keisuke,Furukawa Ryuji,Tsuruta Shotarou,Ueda Yasuo,Taura Naota,Shibata Hidetaka,Fujimoto Masumi,Toriyama Kan,Eguchi Katsumi

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-007-9007-4.pdf

Reference38 articles.

1. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999;22:41–6.

2. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003;52:914.

3. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004;39:909–14.

4. Lonardo A, Loria P, Leonardi F, Ganazzi D, Carulli N. Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol 2002;97:1071–2.

5. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 2005;15:19–27.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials;European Journal of Gastroenterology & Hepatology;2024-07-08

2. Impact of liver specific survival motor neuron (SMN) depletion on peripheral and central nervous system tissue pathology;2024-05-22

3. Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: insights into oxidative stress;Frontiers in Endocrinology;2024-05-21

4. MASH clinical trials and drugs pipeline: An impending tsunami;Hepatology;2024-03-19

5. Insulin-like growth factor binding protein 3 promoter variant (rs2854744) is associated with nonalcoholic fatty liver disease;ARCH ENDOCRIN METAB;2024